×
CSL Receivables 2017-2024 | CSLLY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
CSL receivables for the quarter ending June 30, 2024 were
$3.021B
, a
30.57% increase
year-over-year.
CSL receivables for 2024 were
$3.021B
, a
34.57% increase
from 2023.
CSL receivables for 2023 were
$2.245B
, a
33.08% increase
from 2022.
CSL receivables for 2022 were
$1.687B
, a
6.04% decline
from 2021.
View More
CSL Receivables 2017-2024 | CSLLY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
CSL receivables for 2024 were
$3.021B
, a
34.57% increase
from 2023.
CSL receivables for 2023 were
$2.245B
, a
33.08% increase
from 2022.
CSL receivables for 2022 were
$1.687B
, a
6.04% decline
from 2021.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$178.8B
Regeneron Pharmaceuticals (REGN)
$126.4B
Vertex Pharmaceuticals (VRTX)
$124.2B
Gilead Sciences (GILD)
$103.4B
Bristol Myers Squibb (BMY)
$100.3B
GSK (GSK)
$88.2B
Alnylam Pharmaceuticals (ALNY)
$35.2B
Argenex SE (ARGX)
$31.2B
BioNTech SE (BNTX)
$29.7B
Biogen (BIIB)
$28.9B
Moderna (MRNA)
$27.7B
Illumina (ILMN)
$20.7B
BeiGene (BGNE)
$19.2B
Genmab (GMAB)
$17.5B
BioMarin Pharmaceutical (BMRN)
$13.4B
Vaxcyte (PCVX)
$13B
Incyte (INCY)
$12.8B
Insmed (INSM)
$12.6B
Exact Sciences (EXAS)
$12.6B
Sarepta Therapeutics (SRPT)
$12B
Bio-Techne Corp (TECH)
$11.9B
QIAGEN (QGEN)
$10.4B
Legend Biotech (LEGN)
$9.3B
Bio-Rad Laboratories (BIO.B)
$9.1B
Roivant Sciences (ROIV)
$8.9B
Ascendis Pharma (ASND)
$8.5B
Intra-Cellular Therapies (ITCI)
$7.9B
Exelixis (EXEL)
$7.9B
Halozyme Therapeutics (HALO)
$7.8B
Repligen (RGEN)
$7.6B